meeting, and may join the consortium. Those wishing to participate will have to pledge a minimum financial contribution, which has not yet been agreed, and share all relevant data. Indeed, the project will have to overcome numerous obstacles to information sharing, such as the fact that physicians in different countries often use entirely different words to describe the same disease.
Draghia-Akli points out that the project could yield major benefits for the emerging field of personalized medicine -another political priority for the NIH and the commission -which also faces the challenge of small populations of patients.
Regulatory agencies such as the US Fo o d an d D r u g Administration and the European Medicines Agency rely on large, randomized and controlled clinical trials when deciding whether to approve new medicines, and one of the aims of the consortium will be to develop alternative clinical-trial methods for diseases that affect few people.
These methods are becoming ever more important now that genome analysis is helping to break down common diseases into ever smaller subclasses. "Soon there will be no disease called breast cancer, " says Draghia-Akli. Instead, the catch-all term will be replaced by "a large number of rare diseases, each of which causes malignant growth in breast tissue and requires individual treatment", she says.
The commission will launch a €100-million (US$140-million) call for research proposals in July, which will support the consortium's scientific goals by focusing heavily on developing appropriate clinical trials. Meanwhile, funding remains in limbo. The previous Congress failed to pass a budget for this year, and November's midterm elections swept a Republican majority into the House of Representatives that is bent on making drastic cuts to government spending. With the two parties deadlocked over the 2011 budget, members have had to opt for a series of short-term measures that maintain 2010 programmes and funding levels. Constellation continues to be funded, delaying work on any new initiative.
Some argue that the roughly $250 million spent on Constellation in the current fiscal year has not been wasted. For example, on 21 March, Lockheed Martin Space Systems, based in Denver, Colorado, unveiled a new simulation centre where engineers will try out docking manoeuvres with the programme's Orion crew capsule. The capsule meets most requirements from the authorization bill and all indications are that it will be selected as the MPCV, says Larry Price, deputy programme manager for Orion. Continuing Constellation's contracts in this way is in NASA's best interests, he says. "As you can imagine, it would have been hugely inefficient to stop something, redistribute the labour force, and start it over againespecially if it's exactly the same, " he says.
Even if NASA finally achieves the clarity Obama promised a year ago, it faces many years with no way to send people into space. The last time the agency had a similar gapbetween the end of the Apollo programme in 1975 and the first shuttle launch in 1981 -it knew what was to come next. The shuttle programme had been announced three years before Apollo's conclusion.
The current situation is much worse, said James Maser, chairman of the corporate membership committee at the American Institute of Aeronautics and Astronautics, during the House subcommittee hearing. 
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